The Adaptive COVID-19 Treatment Trial (ACTT) — BETH BASELER (LEIDOS BIOMEDICAL RESEARCH, INC.)
To support randomized, controlled clinical trials to evaluate the safety and efficacy of investigational antiviral drugs against COVID-19.
| Project title | The Adaptive COVID-19 Treatment Trial (ACTT) |
|---|---|
| Project number | 75N91019D00024-P00004-759102000010-1 |
| PI name | BETH BASELER |
| Institution | LEIDOS BIOMEDICAL RESEARCH, INC. |
| Funding mechanism | N01 |
| Agency | NIAID |
| Award amount | $25.08M |
| Fiscal year | 2021 |
| Project start | 2020-04-03T00:00:00 |
| Project end | 2025-04-02T00:00:00 |
| Abstract | To support randomized, controlled clinical trials to evaluate the safety and efficacy of investigational antiviral drugs against COVID-19. |
| Key terms | <Antiviral Agents><Antiviral Drugs><Antivirals><COVID-19><COVID-19 therapeutics><COVID-19 therapy><C |
$799/mo
Try GrantRadar →